华纳药厂(688799.SH)：拟购买、出售资产

Core Viewpoint - Warner Pharmaceuticals (688799.SH) is advancing its "combination of generic and innovative drugs" development strategy by focusing on enhancing its core competitiveness through self-research, collaborative research, and investment incubation [1] Group 1: Strategic Development - The company is implementing a strategy that integrates generic drug development with innovative drug breakthroughs, aligning with industry trends and its own business development strategy [1] - The subsidiary, Qianlie Pharmaceuticals, is focusing on the ophthalmic medication sector, optimizing its product layout, and developing market-potential ophthalmic drugs [1] Group 2: Transaction Details - The company plans to purchase five formulation projects from Qianlie Pharmaceuticals, including Indocyanine Green Injection and Sodium Fluorescein Injection, for a total price of 10.1 million yuan, funded by the company's own resources [1] - The company intends to sell four formulation projects, including Diquafosol Sodium Eye Drops, to Qianlie Pharmaceuticals for a total price of 7 million yuan [1]